The research group “Selection and adaptation of metastasis founder cells” (Dr. Miodrag Gužvić), part of the Chair of Experimental Medicine and Therapy Research (Head: Prof. Dr. Christoph Klein), Faculty of Medicine, University of Regensburg, Germany, is looking for a highly motivated PhD student (f/m).
The position is available from 17.09.2018 and is initially limited to 3 years with a possibility for extension. The salary will be based on TV-L E13.
Early disseminated cancer cells (DCC) that can be detected in the bone marrow (BM) aspirates of prostate cancer patients are founder cells of later arising lethal metastasis. Therefore, molecular characterization of DCCs is of utmost importance for devising the therapeutic strategies to combat metastasis. In this project, we wish to establish an in vitro 3D model of human bone marrow-DCC interaction. Methods that will be used encompass (but are not limited to) cell culture, immuno-fluorescence staining and microscopy, single cell analysis, transcriptome analysis, etc. The candidate will work on a part of DFG-funded project “Molecular Characterization of Bone Metastasis Founder Cells in Prostate Cancer“, within a SPP consortium µBone.
The project will be performed in collaboration with the Centre for Translational Bone, Joint and Soft Tissue Research, Faculty of Medicine, TUM Dresden, Department of Urology, Hospital St. Josef, Regensburg, and the Division of Personalized Cancer Therapy of Fraunhofer–ITEM-R.
- Gužvić et al. Combined genome and transcriptome analysis of single disseminated cancer cells from bone marrow of prostate cancer patients reveals unexpected transcriptomes. Cancer Res. 2014;74(24):7383-7394
- Gužvić M, Klein CA. Towards prevention of metastatic prostate cancer: recent molecular insights from the direct analysis of metastatic precursor cells. Translational Cancer Research 2016, 5(S2):S182-S186
- Klein CA. Selection and adaptation during metastatic cancer progression. Nature. 2013;501(7467):365-72
- graduated recently with a MSc/Diplom(a) degree (or equivalent) from a programme related to molecular biology (Biology or Biochemistry with major/focus/thesis in molecular biology, molecular medicine, or similar) and has a passion for cancer research,
- is a teamplayer, who can also work on their own, with experience in using techniques and methods of molecular biology (mammalian cell culture, PCR, western blot, microscopy, etc.); knowledge of advanced methods (CRISPR/Cas, Lentiviral transduction, 3D cultures, etc.) is a plus,
- is fluent in English, and has excellent oral and written communication skills.
The successful candidate will be involved into one of the graduate schools at the University of Regensburg (RIGEL, BIOMEDIGS, iPUR).
For further information and application, contact Dr. Miodrag Gužvić (firstname.lastname@example.org)
Please send your CV indicating your expertise and skills, transcripts of studies records, the names of two referees, and a motivation letter stating why are you interested in this particular topic and what makes you the right candidate, to email@example.com. Potential candidates will be contacted for in-person interview.
The University of Regensburg is committed to the compatibility of family and career (for more information, please visit http://www.uni-regensburg.de/equal-opportunities). Severely disabled applicants are given preference in instances where applicants demonstrate an equal level of qualification. Please mention any severe disabilities, if applicable, in the application. Unfortunately, we do not provide reimbursement for expenses associated with interviewing.